NKTR Share Price

Open 18.24 Change Price %
High 19.22 1 Day 1.00 5.51
Low 18.13 1 Week 1.07 5.91
Close 19.16 1 Month -0.12 -0.62
Volume 953493 1 Year 4.07 26.97
52 Week High 24.88
52 Week Low 11.41
NKTR Important Levels
Resistance 2 20.17
Resistance 1 19.75
Pivot 18.84
Support 1 18.57
Support 2 18.15
NASDAQ USA Most Active Stocks
DCTH 0.27 22.73%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RLOG 0.45 32.35%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
HAUP 0.10 25.00%
AMCN 2.36 23.56%
DCTH 0.27 22.73%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
PTSX 0.12 -40.00%
More..

Nektar Therapeutics (NASDAQ: NKTR)

NKTR Technical Analysis 1.5
As on 21st Jun 2017 NKTR Share Price closed @ 19.16 and we RECOMMEND Buy for LONG-TERM with Stoploss of 16.22 & Sell for SHORT-TERM with Stoploss of 19.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
NKTR Target for June
1st Target up-side 22.18
2nd Target up-side 23.79
3rd Target up-side 25.4
1st Target down-side 17.58
2nd Target down-side 15.97
3rd Target down-side 14.36
NKTR Other Details
Segment EQ
Market Capital 1016949312.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.nektar.com
NKTR Address
NKTR
455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
Phone: 415-482-5300
Fax: 415-339-5300
NKTR Latest News
Interactive Technical Analysis Chart Nektar Therapeutics ( NKTR NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nektar Therapeutics
NKTR Business Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company which develops a pipeline of drug candidates that utilize company platforms. The Company's product pipeline is consisted of early to late stage drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Its research and development activities involve both small molecule and biologic drug candidates. It creates drug candidates by using its advanced polymer conjugate technologies to modify the chemical structure of pharmacophores to create new molecular entities. Its drug candidate, naloxegol (formerly known as NKTR-118), is an oral opioid antagonist, which has completed Phase III clinical studies for the treatment of opioid-induced constipation (OIC) in patients with non-cancer pain. Its second drug candidate, etirinotecan pegol (also known as NKTR-102), is a topoisomerase I inhibitor, which is under Phase III clinical study as of December 31, 2012.